A blinded placebo (P)-controlled phase I/II dose-escalation study (DES) of brivanib (B), an oral selective dual inhibitor of FGF and VEGF signaling, in combination with cetuximab (C) and irinotecan (I) in patients (pts) with KRAS wild-type (KWT) advanced or metastatic colorectal cancer (annCRC): Safety tolerability, and pharmacokinetics (PK) findings.

被引：0
|
作者：
Park, Y.
El-Khoueiry, A. B.
Gracian, A. C.
Pfeifer, P.
Chacon, M.
Amadori, D.
Fokstuen, T.
Chemidlin, J.
Kollia, G.
Nuyten, D. S.
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Internal Med, Seoul, South Korea
[2] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[3] Ctr Integral Oncol Clara Campal, Madrid, Spain
[4] Odense Univ Hosp, DK-5000 Odense, Denmark
[5] Inst Alexander Fleming, Buenos Aires, DF, Argentina
[6] IRST, Meldola, Italy
[7] Karolinska Univ Hosp, Stockholm, Sweden
[8] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e13552
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13552
引用
收藏
页数：2
相关论文
共 6 条
  • [1] A BLINDED PLACEBO (P) CONTROLLED PHASE 1/2 DOSE ESCALATION STUDY (DES) OF BRIVANIB (B), AN ORAL SELECTIVE DUAL INHIBITOR OF FGF AND VEGF SIGNALING, IN COMBINATION WITH CETUXIMAB (C) AND IRINOTECAN (I) IN PATIENTS (PTS) WITH KRAS WILD TYPE (KWT) ADVANCED OR METASTATIC COLORECTAL CANCER (AMCRC): SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) FINDINGS
    Park, Y. S.
    El-Khoueiry, A.
    Cubillo, A.
    Pfeifer, P.
    Chacon, M.
    Amadori, D.
    Fokstuen, T.
    Chemidlin, J. M.
    Kollia, G.
    Nuyten, D. S. A.
    ANNALS OF ONCOLOGY, 2010, 21 : 199 - 199
  • [2] Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-Met inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy
    Eng, C.
    Bendell, J. C.
    Bessudo, A.
    Gabrail, N. Y.
    Diamond, J.
    Pande, A. U.
    Gorbatchevsky, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [3] Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy
    Bessudo, A.
    Bendell, J. C.
    Gabrail, N.
    Kopp, M. V.
    Mueller, L.
    Hart, L. L.
    Vladimirov, V. I.
    Pande, A. U.
    Gorbatchevsky, I.
    Eng, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study
    Zhang, Wen
    Han, Xiaohong
    Yang, Lin
    Song, Yuanyuan
    Xie, Liangzhi
    Gai, Wenlin
    Wang, Yan
    Shi, Yuankai
    BMC CANCER, 2022, 22 (01)
  • [5] Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study
    Wen Zhang
    Xiaohong Han
    Lin Yang
    Yuanyuan Song
    Liangzhi Xie
    Wenlin Gai
    Yan Wang
    Yuankai Shi
    BMC Cancer, 22
  • [6] A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy.
    Eng, Cathy
    Hart, Lowell L.
    Severtsev, Aleksey
    Gladkov, Oleg
    Mueller, Lothar
    Kopp, Mikhail V.
    Vladimirov, Vladimir Ivanovich
    Langdon, Robert M.
    Kotiv, Bogdan
    Barni, Sandro
    Hsu, Ching
    Bolotin, Ellen
    Von Roemeling, Reinhard
    Schwartz, Brian E.
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
1